B7-33 is a single-chain analog of human relaxin-2 that selectively activates the RXFP1 receptor, and it is easier to manufacture than relaxin itself. In animal models it reduced fibrosis markers and tissue scarring in liver, kidney, and cardiac tissue, comparably to native relaxin. The entire evidence base is preclinical.
- Selectively activates RXFP1, the receptor behind relaxin's anti-fibrotic, tissue-softening signaling.PubMed: B7-33 relaxin
- In animal models it lowered fibrosis markers and tissue scarring across liver, kidney, and cardiac tissue.Animal models
- Those organ-protective effects tracked comparably to native relaxin, in a peptide that is easier to synthesize.Preclinical vs native relaxin
- Nothing here has been reproduced in people: there is no human safety, efficacy, or dosing data at all.Peptide Guide safety review
- Relaxin signaling acts broadly on the vasculature and connective tissue, and it acts on reproductive tissue, so pregnancy is a hard exclusion.Contraindications